SCHEPIS, Filippo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.784
AS - Asia 7.326
EU - Europa 6.020
SA - Sud America 1.152
Continente sconosciuto - Info sul continente non disponibili 264
AF - Africa 187
OC - Oceania 42
Totale 28.775
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.472
SG - Singapore 2.152
CN - Cina 2.001
GB - Regno Unito 1.635
IT - Italia 1.447
BR - Brasile 870
VN - Vietnam 771
HK - Hong Kong 747
DE - Germania 718
BD - Bangladesh 529
SE - Svezia 480
FI - Finlandia 446
RU - Federazione Russa 302
KR - Corea 250
FR - Francia 231
UA - Ucraina 194
TR - Turchia 166
CA - Canada 141
ID - Indonesia 141
IN - India 140
AR - Argentina 102
BG - Bulgaria 93
MX - Messico 91
NL - Olanda 78
ES - Italia 76
JP - Giappone 66
PL - Polonia 54
AE - Emirati Arabi Uniti 49
ZA - Sudafrica 49
IQ - Iraq 44
BE - Belgio 41
CO - Colombia 41
PK - Pakistan 37
AU - Australia 34
EC - Ecuador 34
LT - Lituania 34
AT - Austria 32
MA - Marocco 32
EG - Egitto 27
CL - Cile 26
VE - Venezuela 24
RO - Romania 22
PH - Filippine 21
UZ - Uzbekistan 21
MY - Malesia 20
SA - Arabia Saudita 19
CZ - Repubblica Ceca 18
KE - Kenya 18
PY - Paraguay 18
PE - Perù 17
DZ - Algeria 15
NP - Nepal 15
IE - Irlanda 14
TH - Thailandia 14
TN - Tunisia 14
CR - Costa Rica 13
IL - Israele 12
JM - Giamaica 12
SK - Slovacchia (Repubblica Slovacca) 12
AZ - Azerbaigian 11
AL - Albania 10
BH - Bahrain 10
CH - Svizzera 10
HN - Honduras 10
KZ - Kazakistan 10
UY - Uruguay 10
BO - Bolivia 9
BY - Bielorussia 9
GT - Guatemala 8
PT - Portogallo 8
DK - Danimarca 7
DO - Repubblica Dominicana 7
GE - Georgia 7
JO - Giordania 7
LB - Libano 7
SC - Seychelles 7
EU - Europa 6
GR - Grecia 6
IR - Iran 6
KG - Kirghizistan 6
LV - Lettonia 6
NI - Nicaragua 6
PA - Panama 6
RS - Serbia 6
CY - Cipro 5
HR - Croazia 5
HU - Ungheria 5
PR - Porto Rico 5
QA - Qatar 5
SI - Slovenia 5
XK - ???statistics.table.value.countryCode.XK??? 5
AM - Armenia 4
BZ - Belize 4
EE - Estonia 4
KH - Cambogia 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
SN - Senegal 4
SY - Repubblica araba siriana 4
TW - Taiwan 4
Totale 28.458
Salva come PNG Salva come JPEG
Città #
Ashburn 1.444
Santa Clara 1.413
Singapore 1.270
Fairfield 1.219
Southend 972
Woodbridge 725
Hong Kong 722
Hefei 707
Chandler 590
Houston 580
Seattle 494
San Jose 453
London 427
Cambridge 417
Wilmington 416
Helsinki 376
Modena 329
Ann Arbor 327
Nyköping 316
Jacksonville 312
Beijing 279
New York 267
Dearborn 255
Los Angeles 255
Ho Chi Minh City 249
Dallas 245
The Dalles 244
Seoul 234
Council Bluffs 229
Berlin 217
Hanoi 190
Chicago 181
San Diego 120
Milan 117
Lauterbourg 102
Princeton 95
Jakarta 92
Sofia 89
Buffalo 86
Moscow 78
Shanghai 77
São Paulo 77
Izmir 75
Frankfurt am Main 74
Bologna 73
Rome 65
Munich 62
Salt Lake City 62
Eugene 56
Orem 54
Tokyo 53
Redwood City 50
Phoenix 44
Boardman 41
Grafing 39
Da Nang 38
Kent 38
Yalova 38
Brooklyn 37
Atlanta 36
Des Moines 35
Nuremberg 35
Tampa 35
Warsaw 35
Elk Grove Village 34
Nanjing 34
Guangzhou 33
Rio de Janeiro 32
Brussels 31
Columbus 30
Toronto 30
Montreal 29
Naples 29
Redondo Beach 29
Haiphong 27
Jersey City 27
Mexico City 27
Bremen 26
Chennai 24
Turku 24
Johannesburg 23
Mumbai 23
Vancouver 23
Boston 22
Falls Church 22
Florence 22
Stockholm 21
Brasília 20
Denver 20
Melbourne 20
Portsmouth 20
Tashkent 19
Amsterdam 18
Charlotte 18
Manchester 18
Miano 18
Wuhan 18
Dubai 17
Paris 17
Baghdad 16
Totale 19.223
Salva come PNG Salva come JPEG
Nome #
Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease 705
04093 Portal hypertension in advanced protoporphyric hepatopathy: a case report 495
04092 Liver function, iron status, and hemopoiesis in erythropoietic protoporphyria (EPP): insights into a complex interplay 486
Liver Angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular cancer after HCV direct-acting antivirals 459
Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study 443
Microenvironment inflammatory infiltrate drives growth speed and outcome of hepatocellular carcinoma: a prospective clinical study 440
Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis 426
Cardiopulmonary hemodynamics and c-reactive protein as prognostic indicators in compensated and decompensated cirrhosis 401
ANTICOAGULANT THERAPY IS SAFE AND EFFECTIVE IN PREVENTING PORTAL VEIN THROMBOSIS (PVT) IN ADVANCED CIRRHOTIC PATIENTS: A PROSPECTIVE RANDOMIZED CONTROLLED STUDY 390
PROGRESSIVE ALTERATIONS IN SYSTEMIC AND CARDIOPULMONARY HEMODYNAMICS OCCUR IN PATIENTS WITH CIRRHOSIS AND PREDICT DEATH IN DECOMPENSATED CIRRHOSIS 380
Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis 379
A new device for ultrasound-guided peripheral venous access 353
Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis 347
JLB: a flexible and effective device in critical patients. Review of clinical cases 340
30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice 333
Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis 330
Guide-wire replacement of a mini-midline catheter with a central venous catheter: A retrospective study on 63 cases 321
Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. 318
Unusual association between Budd–Chiari syndrome secondary to antiphospholipid syndrome and relapsing polychondritis: a case report and review of the literature 316
ENOXAPARIN PREVENTS PORTAL VEIN THROMBOSIS (PVT) AND DECOMPENSATION IN ADVANCED CIRRHOTIC PATIENTS: FINAL REPORT OF A PROSPECTIVE RANDOMIZED CONTROLLED STUDY 313
De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients 307
Low molecular weight heparin does not increase bleeding and mortality post endoscopic variceal band ligation in cirrhotic patients 305
Consensus conference on TIPS management: Techniques, indications, contraindications 304
Validating, deconstructing and refining Baveno criteria for ruling out high-risk varices in patients with compensated cirrhosis 299
Liver steatosis and non-alcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV 295
Complete resolution of non-necrotizing lung granuloma and pyoderma gangrenosum after restorative proctocolectomy in a woman with severe ulcerative colitis and cytomegalovirus infection 294
Obese zebrafish: A small fish for a major human health condition 293
Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study 290
Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: A case-control study 289
Prevention and Management of Bleeding Risk Related to Invasive Procedures in Cirrhosis 289
The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias 286
Ccdc80-l1 Is involved in axon pathfinding of zebrafish motoneurons. 285
Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study 278
Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference 278
Cloning and molecular characterization of a novel gene strongly induced by the adenovirus E1A gene in rat thyroid cells. 276
Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials 275
LOW MOLECULAR WEIGHT HEPARIN TREATMENT DOES NOT INCREASE THE RISK OF BLEEDING AFTER PROPHYLACTIC ENDOSCOPIC VARICEAL BAND LIGATION IN PATIENTS WITH CIRRHOSIS 275
Angiopoietin-2/Tie2 Inhibition by Regorafenib Associates With Striking Response in a Patient With Aggressive Hepatocellular Carcinoma 271
Baveno VII – Renewing consensus in portal hypertension 260
Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. 258
A RANDOMIZED TRIAL OF THE SAFETY AND HEPATIC HEMODYNAMIC EFFECTS OF INTRAVENOUS CONIVAPTAN IN EUVOLEMIC OR HYPERVOLEMIC CIRRHOTIC PATIENTS 257
Chemoprevention of hepatocellular carcinoma 255
The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. 250
MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA mismatch repair protein MLH1 248
Natural history of chronic HBV in northern Italy: Morbidity and morality after 30 years 247
Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: a long-term follow-up study 244
Protection of human endothelial cells from oxidative stress: Role of Ras-ERK1/2 signaling 242
Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation 238
PROCALCITONIN IS THE BEST DIAGNOSTIC AND PROGNOSTIC MARKER OF SEPSIS IN DECOMPENSATED CIRRHOTIC PATIENTS 238
Effects of simvastatin treatment on sICAM-1 and sE-selectin levels in hypercholesterolemic subjects. 237
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19 237
Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives 236
Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection? 235
Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis 233
When and how to treat acute hepatitis C? 232
Reply to: “Relationship of hyperdynamic circulation and cardiodynamic states in cirrhosis” 228
Cardiodynamic state is associated with systemic inflammation and fatal acute-on-chronic liver failure 227
The Coiled-Coil Domain Containing 80 (ccdc80) gene regulates gadd45β2 expression in the developing somites of zebrafish as a new player of the hedgehog pathway 226
Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors. 225
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. 225
Thrombophilic genetic risk factors for liver fibrosis: To screen or not to screen? 222
Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease 222
Relevance of spontaneous portosystemic shunts detected with CT in patients with cirrhosis 219
5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial 217
Paradoxical embolization in TIPS: take a closer look to the heart 217
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model 216
Outcome of liver disease and response to interferon treatment are not influenced by hepatitis B virus core gene variability in children with chronic type B hepatitis. 215
Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF) 214
An adenovirus carrying the rat protein tyrosine phosphatase eta suppresses the growth of human thyroid carcinoma cell lines in vitro and in vivo. 213
Transjugular Intrahepatic Portosystemic Shunt: Devices Evolution, Technical Tips and Future Perspectives 212
Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma 206
Alcoholic and Nonalcoholic Liver Disease: Diagnostic Assessment and Therapeutic Perspectives 203
The role of transjugular intrahepatic portosystemic shunt in patients with cirrhosis and ascites: Recent evolution and open questions 199
Preoperative chemoradiotherapy for oesophageal cancer: A systematic review and meta-analysis 199
Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomes 198
Transjugular intrahepatic portosystemic shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: a real-life, case-control study 196
Hepatic encephalopathy increases the risk for mortality and hospital readmission in decompensated cirrhotic patients: a prospective multicenter study 189
Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis 188
Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study 188
Prevalence, Predictors, and Severity of Lean Nonalcoholic Fatty Liver Disease in Patients Living With Human Immunodeficiency Virus 187
Pathophysiology of portal hypertension and variceal bleeding 184
Physical activity in liver transplant recipients: a large multicenter study 176
Transient elastography and ultrasonography: Optimal evaluation of liver fibrosis and cirrhosis in patients with chronic hepatitis B concurrent with nonalcoholic fatty liver disease 175
Akt1/Akt2 inhibition and development of hepatocellular carcinoma 174
Prediction of Esophageal Varices by Liver Stiffness and Platelets in Persons with HIV infection and Compensated Advanced Chronic Liver Disease 173
Performance of spleen stiffness measurement to rule out high-risk varices in patients with porto-sinusoidal vascular disorder 171
Angiopoietin-2 and the Vascular Endothelial Growth Factor Promote Migration and Invasion in Hepatocellular Carcinoma- and Intrahepatic Cholangiocarcinoma-Derived Spheroids 169
Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation 169
Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS 167
Differential Impact of Tumor Endothelial Angiopoietin-2 and Podoplanin in Lymphatic Endothelial Cells on HCC Outcomes with Tyrosine Kinase Inhibitor Treatment According to Sex 164
Porto-sinusoidal vascular liver disorder with portal hypertension: Natural history and long-term outcome 164
Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease 163
Meta-analysis of Transarterial Embolization in Patients with Unresectable Hepatocellular Carcinoma: Dr Camma and colleagues respond 160
Liver Transplantation for Porto-sinusoidal Vascular Liver Disorder: Long-term Outcome 159
Effects of sildenafil on right ventricle remodelling in Portopulmonary hypertension 158
The Neoangiogenic Transcriptomic Signature Impacts Hepatocellular Carcinoma Prognosis and Can Be Triggered by Transarterial Chemoembolization Treatment 156
Monitoring Treatment of Cirrhosis and Portal Hypertension 155
Erratum: Unusual association between Budd-Chiari syndrome secondary to antiphospholipid syndrome and relapsing polychondritis: A case report and review of the literature (Clinical Rheumatology (2013) 32 (905-907) DOI: 10.1007/s10067-013-2229-z) 153
Reply to: “It takes two “eyes” to see in depth” 153
Corrigendum to ‘Baveno VII – Renewing consensus in portal hypertension’ [J Hepatol (2022) 959-974, (S0168827821022996), (10.1016/j.jhep.2021.12.022)] 152
Totale 25.857
Salva come PNG Salva come JPEG
Categoria #
all - tutte 115.194
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 115.194
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.862 132 156 157 66 76 111 132 154 208 144 315 211
2022/20231.721 214 206 139 163 151 258 21 174 178 29 125 63
2023/20241.153 50 62 78 118 183 90 152 113 62 21 88 136
2024/20255.239 135 63 66 336 983 742 344 390 764 306 520 590
2025/202611.479 761 570 1.067 1.190 1.250 923 1.218 574 1.039 1.170 835 882
2026/2027401 401 0 0 0 0 0 0 0 0 0 0 0
Totale 28.775